209 related articles for article (PubMed ID: 23779109)
1. Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.
Stawikowska R; Cudic M; Giulianotti M; Houghten RA; Fields GB; Minond D
J Biol Chem; 2013 Aug; 288(31):22871-9. PubMed ID: 23779109
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.
Minond D; Cudic M; Bionda N; Giulianotti M; Maida L; Houghten RA; Fields GB
J Biol Chem; 2012 Oct; 287(43):36473-87. PubMed ID: 22927435
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition.
Chavaroche A; Cudic M; Giulianotti M; Houghten RA; Fields GB; Minond D
Anal Biochem; 2014 Mar; 449():68-75. PubMed ID: 24361716
[TBL] [Abstract][Full Text] [Related]
4. SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.
Knapinska AM; Dreymuller D; Ludwig A; Smith L; Golubkov V; Sohail A; Fridman R; Giulianotti M; LaVoi TM; Houghten RA; Fields GB; Minond D
J Med Chem; 2015 Aug; 58(15):5808-24. PubMed ID: 26192023
[TBL] [Abstract][Full Text] [Related]
5. Substrate conformation modulates aggrecanase (ADAMTS-4) affinity and sequence specificity. Suggestion of a common topological specificity for functionally diverse proteases.
Lauer-Fields JL; Minond D; Sritharan T; Kashiwagi M; Nagase H; Fields GB
J Biol Chem; 2007 Jan; 282(1):142-50. PubMed ID: 17095512
[TBL] [Abstract][Full Text] [Related]
6. In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators.
Bienstein M; Minond D; Schwaneberg U; Davari MD; Yildiz D
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163294
[TBL] [Abstract][Full Text] [Related]
7. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10.
Caescu CI; Jeschke GR; Turk BE
Biochem J; 2009 Oct; 424(1):79-88. PubMed ID: 19715556
[TBL] [Abstract][Full Text] [Related]
8. Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate.
Madoux F; Dreymuller D; Pettiloud JP; Santos R; Becker-Pauly C; Ludwig A; Fields GB; Bannister T; Spicer TP; Cudic M; Scampavia LD; Minond D
Sci Rep; 2016 Dec; 6(1):11. PubMed ID: 28442704
[TBL] [Abstract][Full Text] [Related]
9. Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases.
Gao W; Zhu J; Westfield LA; Tuley EA; Anderson PJ; Sadler JE
J Biol Chem; 2012 Aug; 287(32):26944-52. PubMed ID: 22707719
[TBL] [Abstract][Full Text] [Related]
10. A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor.
Düsterhöft S; Höbel K; Oldefest M; Lokau J; Waetzig GH; Chalaris A; Garbers C; Scheller J; Rose-John S; Lorenzen I; Grötzinger J
J Biol Chem; 2014 Jun; 289(23):16336-48. PubMed ID: 24790088
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor α ectodomain shedding.
Schwarz J; Schmidt S; Will O; Koudelka T; Köhler K; Boss M; Rabe B; Tholey A; Scheller J; Schmidt-Arras D; Schwake M; Rose-John S; Chalaris A
J Biol Chem; 2014 Jan; 289(5):3080-93. PubMed ID: 24338472
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of pro-tumor necrosis factor alpha by ADAM metallopeptidase domain 17: a fluorescence-based protease assay cleaves its natural protein substrate.
Zhang C; Zheng L; Nurnberg J; Vacari BM; Zhou J; Wang Y
Anal Biochem; 2014 Jan; 445():14-9. PubMed ID: 24096196
[TBL] [Abstract][Full Text] [Related]
13. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries.
Tucher J; Linke D; Koudelka T; Cassidy L; Tredup C; Wichert R; Pietrzik C; Becker-Pauly C; Tholey A
J Proteome Res; 2014 Apr; 13(4):2205-14. PubMed ID: 24635658
[TBL] [Abstract][Full Text] [Related]
14. Meprin β induces activities of A disintegrin and metalloproteinases 9, 10, and 17 by specific prodomain cleavage.
Wichert R; Scharfenberg F; Colmorgen C; Koudelka T; Schwarz J; Wetzel S; Potempa B; Potempa J; Bartsch JW; Sagi I; Tholey A; Saftig P; Rose-John S; Becker-Pauly C
FASEB J; 2019 Nov; 33(11):11925-11940. PubMed ID: 31381863
[TBL] [Abstract][Full Text] [Related]
15. ADAM proteases: Emerging role and targeting of the non-catalytic domains.
Saha N; Robev D; Himanen JP; Nikolov DB
Cancer Lett; 2019 Dec; 467():50-57. PubMed ID: 31593799
[TBL] [Abstract][Full Text] [Related]
16. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling.
Bozkulak EC; Weinmaster G
Mol Cell Biol; 2009 Nov; 29(21):5679-95. PubMed ID: 19704010
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Juxtamembrane Segment of ADAM17 Interacts with Membranes and Is Essential for Its Shedding Activity.
Düsterhöft S; Michalek M; Kordowski F; Oldefest M; Sommer A; Röseler J; Reiss K; Grötzinger J; Lorenzen I
Biochemistry; 2015 Sep; 54(38):5791-801. PubMed ID: 26348730
[TBL] [Abstract][Full Text] [Related]
18. Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.
Folkesson M; Li C; Frebelius S; Swedenborg J; Wågsäter D; Williams KJ; Eriksson P; Roy J; Liu ML
Thromb Haemost; 2015 Nov; 114(6):1165-74. PubMed ID: 26422658
[TBL] [Abstract][Full Text] [Related]
19. Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine.
Schweigert O; Dewitz C; Möller-Hackbarth K; Trad A; Garbers C; Rose-John S; Scheller J
Biochim Biophys Acta; 2014 Feb; 1843(2):275-87. PubMed ID: 24286866
[TBL] [Abstract][Full Text] [Related]
20. The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site.
Wong E; Maretzky T; Peleg Y; Blobel CP; Sagi I
J Biol Chem; 2015 May; 290(19):12135-46. PubMed ID: 25795784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
